Nexavar is owned by Bayer Hlthcare.
Nexavar contains Sorafenib Tosylate.
Nexavar has a total of 3 drug patents out of which 0 drug patents have expired.
Nexavar was authorised for market use on 20 December, 2005.
Nexavar is available in tablet;oral dosage forms.
Nexavar can be used as treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; treatment of advanced renal cell carcinoma; treatment of unresectable hepatocellular carcinoma, treatment of advanced renal cell carcinoma, treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma..
The generics of Nexavar are possible to be released after 10 September, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8877933||BAYER HLTHCARE||Thermodynamically stable form of a tosylate salt|| |
(4 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8618141||BAYER HLTHCARE||Aryl ureas with angiogenesis inhibiting activity|| |
(10 days from now)
|US9737488||BAYER HLTHCARE||Pharmaceutical composition for the treatment of cancer|| |
(5 years from now)
Market Authorisation Date: 20 December, 2005
Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; Treatment of unresectable hepatocellular carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic